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Abstract: Extracellular matrix degradation by matrix metalloproteinases (MMPs) plays a 
pivotal role in cancer progression by promoting motility, invasion and angiogenesis. 
Studies have shown that MMP expression is increased in head and neck squamous cell 
carcinomas (HNSCCs), one of the most common cancers in the world, and contributes to 
poor outcome. In this review, we examine the expression pattern of MMPs in HNSCC by 
microarray datasets and summarize the current knowledge of MMPs, specifically MMP-1, 
-3, -7 -10, -12, -13, 14 and -19, that are highly expressed in HNSCCs and involved cancer 
invasion and angiogenesis. 
Keywords: matrix metalloproteinase; invasion; angiogenesis; head and neck squamous 
cell carcinoma 
 
1. Introduction 
Cancer is a major disease and cause of death in the world. Over 1.5 million people in the United 
States were diagnosed with cancer in 2012, and 2.5% of all cancer cases were head and neck squamous 
cell carcinomas (HNSCCs) [1,2]. Metastatic dissemination of HNSCCs initially occurs to the regional 
lymph nodes in the neck, and high mortality and poor prognosis of HNSCCs are predicted by 
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occurrence of lymph node metastasis [3]. In some tumor types including HNSCCs, local invasion of 
the tumor is rarely controlled by surgery alone. There is a pressing need for new therapeutic 
interventions that target invasive and metastatic HNSCCs. 
The extracellular matrix (ECM) undergoes significant remodeling during tumor progression, which 
is mediated largely by extracellular proteinases, particularly the matrix metalloproteinases (MMPs) [4]. 
MMPs represent a family of zinc-dependent proteinases, which degrade ECM components, such as 
collagens and proteoglycans, and they have a role not only in normal development and tissue damage 
in various pathophysiological conditions such as arthritis and wound healing but also in tumor 
development [5]. MMPs have been implicated in the promotion of tumor invasion and metastasis for 
decades [6]. More than 20 different human MMPs have been identified [7], and many MMPs are 
expressed and contribute to HNSCC progression [8,9]. 
2. MMP Expression in HNSCCs 
Widespread use of gene expression microarrays has identified potential candidate genes in 
HNSCCs. Further investigation of the biological behaviors and significant clinical outcome of these 
genes in HNSCCs is of great interest. We previously established a HNSCC cell line, MSCC-1, from 
lymph node metastasis, and then we isolated a highly invasive clone, MSCC-Inv1, from MSCC-1 
using an in vitro invasion assay device (Figure 1) [4]. Gene expression profiles of both MSCC-1 and 
MSCC-Inv1 were compared by microarray analysis, and invasion-related molecules, such as periostin 
(originally named osteoblast-specific factor-2), interferon-induced transmembrane protein 1 (IFITM1) 
and Wnt-5b were identified (Figure 1) [10–12]. From these results, MMP-19 and membrane type  
1-MMP (MT1-MMP) were also identified as cancer invasion-related factors (Figure 1 and Table 1). 
Interestingly, the highly invasive cell lines with overexpression of these three genes (periostin, IFITM1 
and Wnt-5b) commonly induced MMP-10 and MMP-13 expression (Figure 1 and Table 1). Pyeon et al. 
have analyzed genome-wide expression profiles of 84 HNSCCs, cervical cancers and site-matched 
normal epithelial samples that were laser-capture-microdissected from adjacent sections. Comparison 
of HNSCCs and normal tissues indicated that expression of MMP-1, -3, -7, -9, -10, -12 and -13 was 
up-regulated in HNSCC cases (Table 2) [13]. In addition, Stokes et al. have reported the expression 
profiles of degradome components in the tumor microenvironment of HNSCCs. In this report, 
comprehensive expression profiling of MMPs was obtained using quantitative real-time reverse 
transcription-PCR analysis of tissue samples representing the tumor (83 cases), the invasive margin 
(41 cases) and adjacent tissue (41 cases) from HNSCC patients, along with normal tissue controls  
(13 cases). The results show that majority of the MMPs were expressed in tumor tissues, both in the 
center and the invasive margin of the tumor, and that the expression was generally increased as 
compared to the normal tissue (Table 3) [14]. Furthermore, Ye et al. have demonstrated that MMP-1,  
-3, -7, -9, -10, -11, -12 and -13 were up-regulated in oral tongue squamous cell carcinoma cases  
(53 primary and 22 matching normal tissues) by genome-wide transcriptomic profiles (Table 4) [15]. 
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Figure 1. Up-regulated MMP genes in highly invasive HNSCC cell lines as compared to 
parental cell lines. Adapted from ref. [10] and Table 1 with modification. 
 
Table 1. Up-regulated MMP genes in highly invasive HNSCC cell lines as compared to 
parental cell lines. Adapted from ref. [10] with modification. Cutoff: Fold increased >2.0. 
Comparison (/Parent Cells) Fold Change Symbol Other Designations 
MSCC-Inv1 2.82 MMP-19 MMP-18, RASI-1 
 2.44 MMP-14 MT1-MMP 
Periostin overexpressing cells 30.2 MMP-1 Interstitial collagenase 
 17.4 MMP-10 Stromelysin 2 
 14.7 MMP-13 Collagenase 3 
 2.9 MMP-28 Epilysin 
 2.6 MMP-3 Stromelysin 1, Progelatinase 
IFITM1 overexpressing cells 19.1 MMP-13 Collagenase 3 
 8.2 MM-12 Macrophage elastase 
 3.6 MMP-10 Stromelysin 2 
 2.8 MMP-11 Stromelysin 3 
Wnt-5B overexpressing cells 7.9 MMP-12 Macrophage elastase 
 7.8 MMP-13 Collagenase 3 
 6.1 MMP-7 Matrilysin, uterine 
 5.8 MMP-10 Stromelysin 2 
 2.8 MMP-14 MT1-MMP 
 2.5 MMP-28 Epilysin 
 2.2 MMP-2 72 kDa gelatinase, type IV collagenase 
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Table 2. Up-regulated MMP genes in HNSCC cases as compared to normal tissues. 
Adapted from ref. [13] with modification. Cutoff: Fold increased >2.0. 
Fold Change Symbol Other Designations 
13.9 MMP-1 Interstitial collagenase 
12.0 MMP-12 Macrophage elastase 
8.6 MMP-10 Stromelysin 2 
8.1 MMP-3 Stromelysin 1 
7.3 MMP-7 Matrilysin, uterine 
7.2 MMP-9 92kDa gelatinase, type IV Collagenase 
5.7 MMP-13 Collagenase 3 
* p value < 0.01; fold increase >2.0. 
Table 3. Up-regulated MMP genes in HNSCC cases as compared to normal tissues. 
Adapted from ref. [14] with modification. 
Symbol Other Designations p value 
MMP-1 Interstitial collaganase ** 
MMP-2 72 kDa gelatinase, type IV collagenase ** 
MMP-3 Stromelysin 1 ** 
MMP-7 Matrilysin, uterine ** 
MMP-8 PMNL collagenase (MNL-CL) * 
MMP-9 92 kDa gelatinase, type IV Collagenase ** 
MMP-10 Stromelysin 2 ** 
MMP-11 Stromelysin 3 ** 
MMP-12 Macrophage elastase ** 
MMP-13 Collagenase 3 ** 
MMP-14 MT1-MMP ** 
MMP-15 MT2-MMP NS 
MMP-16 MT3-MMP ** 
MMP-17 MT4-MMP ** 
MMP-19 MMP-18, RASI-1 ** 
MMP-23 CA-MMP ** 
MMP-24 MT5-MMP ** 
MMP-25 MT6-MMP ** 
MMP-27 MMP-27 NS 
MMP-28 Epilysin NS 
p value: *, p = 0.01–0.05; **, p < 0.001; NS, not significant. 
Taken together with results of MMP gene expression profiling in HNSCCs (Tables 1–4), MMP-1,  
-3, -7, -10, -12 and -13 may strongly correlate with HNSCC tumorigenicity and progression (Figure 2). 
To confirm the MMP expression pattern in Figure 2, 11 MMPs (MMP-1, -2, -3, -7, -9, -10, -11, -12,  
-13, -14 and -19) that increased in at least two independent gene expression profiling datasets were 
examined by the Oncomine public cancer microarray database [16]. As expected, MMP-1, -3, -7, -10,  
-12 and -13 (identified as the most highly expressed MMPs in HNSCC by four independent gene 
expression datasets in Figure 2) were significantly increased in almost all HNSCC microarray datasets 
(Table 5 and Figure 3). In Table 5, MMP-1, -3, -7, -9, -10, -11, -12 and -13 demonstrate strong 
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significance and correlation between the six cited studies, MMP-2, -14 and -19 did not. This may be 
attributed to the fact that RNA samples used in each profiling datasets were obtained from different 
stage of HNSCC. Therefore, we think that MMP-2, -14 and -19 were not up-regulated in some 
datasets. In fact, our previous study showed that MMP-14 expression is significantly increased in 
highly invasive cell line, MSCC-inv1 cells compare to parent cells. These findings suggest that some 
of MMP expression may be locally regulated in part of tumor tissue. 
Table 4. Up-regulated MMP genes in HNSCC cases as compared to normal tissues. 
Adapted from ref. [15] with modification. Cutoff: Fold increased >2.0.  
Fold Change Symbol Other Designations 
57.6 MMP-1 Interstitial collaganase 
8.4 MMP-10 Stromelysin 2 
8.4 MMP-3 Stromelysin 1 
7.8 MMP-12 Macrophage elastase 
4.1 MMP-9 92 kDa gelatinase, type IV Collagenase 
3.8 MMP-13 Collagenase 3 
2.8 MMP-7 Matrilysin, uterine 
2.0 MMP-11 Stromelysin 3 
Figure 2. Venn diagram depicting the extent of overlap between the MMP expression 
profiles from Tables 1–4. 
 
In this review, we will summarize the role of these MMPs that are highly expressed in HNSCCs, 
especially MMP-1, -3, -7, -9, -10, -12, -13 and -19, and also review the roles of MMP-14, which is one 
of the key molecules involved in HNSCC progression through invadopodia formation.  
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Table 5. MMP expression in HNSCCs using the Oncomine gene expression database. 
Human HNSCC samples (n = 201) compared against normal tissues (n = 109) from six 
independent microarray datasets for MMP expression using the Oncomine database. These 
six datasets (including two microarray datasets from Tables 2 and 4) were chosen because 
all other datasets analyzed by less than 10 samples both in normal and in HNSCC were 
removed. * p < 0.05. 
Number Author 
Number of 
samples  
MMP-1 MMP-3 MMP-7 MMP-10 MMP-12 
Normal HNSCC 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
1 Estilo 26 31 61.7 * 14.6 * 3.0 * 23.6 * 5.8 * 
2 Ginos 13 41 221.8 * 11.9 * 7.5 * 14.9 * 15.6 * 
3 Peng 22 57 86.3 * 29.9 * 4.8 * 25.6 * 17.3 * 
4 Pyeon 10 15 137.5 * 19.0 * 3.8 * 24.1 * 27.6 * 
5 Talbot 26 31 27.7 * 3.5 * 1.5 0.066 4.0 * 4.1 * 
6 Ye 12 26 124.6 * 10.6 * 2.2 * 6.4 * 7.3 * 
Total 109 201 
Number Author 
MMP-13 MMP-9 MMP-11 MMP-2 MMP-14 MMP-19 
Fold 
Change 
P value 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
Fold 
Change 
p 
value 
1 Estilo 20.3 * 9.5 * 2.3 * 1.1 0.356 1.9 * -1.2 0.953 
2 Ginos 15.2 * 11.8 * 5.3 * 2.2 * 1.8 * 8.8 * 
3 Peng 9.2 * 3.8 * 2.3 * 1.4 * 2.1 * 1.2 * 
4 Pyeon 4.3 * 8.1 * 1.4 * 1.8 * 1.0 0.257 1.1 0.286 
5 Talbot 4.7 * 3.2 * 1.6 * 1.0 0.439 1.1 * -1.2 1 
6 Ye 4.0 * 4.6 * 1.5 * 1.1 0.055 1.1 0.159 1.1 0.201 
Figure 3. The heat map of MMP expression in HNSCC. Each number of analyses is 
corresponding to Table 3. The heat map intensity corresponds to percentile  
overexpression (red). 
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3. Roles of MMPs in HNSCCs 
3.1. MMP-1 in HNSCCs 
MMP-1, interstitial collagenase, degrades components of the ECM, such as many types of collagens 
and proteoglycans. Expression of MMP-1 has been observed in various cancers such as breast, 
colorectal, gastric and esophageal cancer, and contributes to cancer progression [17–23]. Animal 
models using tissue-specific overexpression of MMP-1 in the suprabasal layer of skin have indicated 
that MMP-1 induced epidermal hyperplasia and increased susceptibility to tumorigenesis [24]. 
Moreover, MMP-1 in the stromal-tumor microenvironment promotes cancer invasion and angiogenesis 
of breast cancers through proteolytic cleavage of PAR-1 (protease-activated receptors), which is one of 
the proteolytically activated G-protein coupled receptors [25,26]. Recent experimental data also show 
that elevated expression of MMP-1 promotes not only breast cancer growth at the primary site 
(orthotopic injection model) but also brain and lung metastases (left ventricle of the heart and tail  
vein injection model) through activation of epidermal growth factor receptor (EGFR) signaling by 
MMP-1-proteolyzed-active TGFα [27]. 
Gene profiling datasets showed that MMP-1 expression was strongly increased in HNSCC cases 
(e.g., 30.2-fold changes in a highly invasive HNSCC cell line, 13.9-fold changes in HNSCC cases and 
57.6-fold changes in tongue squamous cell carcinoma cases (Tables 1, 2 and 4, respectively)) [13–15]. 
In addition, other reports have also suggested that MMP-1 expression is up-regulated in  
HNSCCs [8,28–31]. Moreover, MMP-1 expression is down-regulated by the tumor-suppressor gene 
p53 via the transactivator AP-1 [32–34]. p53 is one of the most important molecules in HNSCC cancer 
tumorigenicity, because somatic mutations in the p53 gene, TP53, have been found in 60%–80% of 
HNSCC cases and were associated with a poor outcome of HNSCCs [35,36]. These findings also 
demonstrate high expression levels of MMP-1 in HNSCCs. On the other hand, a more recent report 
indicates that elevation of p53 protein levels by cisplatin or 5-FU was markedly reduced by 
overexpression of periostin in gastric cancer cells [10]. This result suggests that periostin-mediated 
inhibition of p53 expression may regulate MMP-1 expression in HNSCCs. In fact, our previous microarray 
analysis shows that MMP-1 expression is dramatically up-regulated in a periostin-overexpressing 
HNSCC cell line as compared to the parent cell line (Figure 1 and Table 1) [10]. However, although 
these studies indicate the importance of MMP-1 expression in cancer malignancy, the detailed 
mechanism of MMP-1 in HNSCC progression is still unknown. 
3.2. MMP-3 in HNSCCs 
MMP-3/stromelysin-1 is highly expressed in the cancer microenvironment because MMP-3 is 
expressed by fibroblasts, endothelial cells and immune cells surrounding the tumor and cancer  
cells [37–40]. In breast cancer, the targeted overexpression of activated MMP-3 in the mammary gland 
induces the transition of normal cells to malignant epithelial cells, suggesting that MMP-3 promotes 
mammary carcinogenesis [41]. In addition, Kessenbrock et al. recently showed that the hemopexin 
domain of MMP-3 regulates the balance between canonical and noncanonical Wnt signaling in a 
nonproteolytic manner and affects adult epithelial stem cell function [42]. These findings suggest that 
MMP-3 potentially regulates cancer stem cells during tumor initiation and metastasis [42]. On the 
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other hand, in HNSCCs, studies have shown that MMP-3 has a protective role in HNSCC 
tumorigenesis. McCawley et al. indicated that treatment of chemical carcinogens in MMP-3-deficient 
mice enhanced tumor growth as compared to control mice [43]. This report suggests that MMP-3 has 
an opposing role in cancer development and progression. However, gene expression profiling datasets 
show a significant increase in MMP-3 expression in HNSCC cases (Tables 1–5), suggesting that 
MMP-3 might have a role in HNSCC initiation or progression. 
Markers of cancer stem cells, such as CD44 and glucose regulated protein 78 (GRP78), have been 
identified in HNSCCs, and cancer stem cells also contribute HNSCC tumorigenicity [44–46]. The 
molecular mechanisms of how MMP-3 affects HNSCC development and/or progression requires 
future investigation. 
3.3. MMP-7 in HNSCCs 
MMP-7/matrilysin is an enzyme that degrades collagens I, III, IV and V, fibronectin, vitronectin, 
laminin and elastin [47] and is expressed in variety of cancers including colon, prostate, esophageal 
and HNSCCs [48–52]. Gene expression analyses also show that MMP-7 is significantly overexpressed 
in almost all HNSCC datasets (Figure 2 and Tables 1–5). In fact, Chuang and colleagues have reported 
that active MMP-7 is associated with invasion in more invasive buccal squamous cell carcinoma [52]. 
Moreover, glutamate decarboxylase 1 (GAD1) is correlated with cellular invasiveness and migration 
by regulating β-catenin translocation and MMP-7 activation [53]. From these reports, although there is 
little doubt that the MMP-7 has an important role in HNSCC progression, its molecular mechanisms 
have not been identified. 
A recent report by Dey et al. identified part of the mechanism of MMP-7 transcriptional regulation [54]. 
They clearly showed that high MMP-7-expressing breast cancer had relatively low phosphatase and 
tensin homolog (PTEN) levels both in clinical cases and cell lines, and the high levels of MMP-7 
expression and enzymatic activity were abrogated by inhibition of phosphoinositide 3-kinase (PI3K), 
which is as main target of PTEN. Moreover, they also showed that higher levels of MMP-7 in  
triple-negative breast cancer patients were associated with poor outcome. Twenty-three percent of 
HNSCCs have PTEN mutations as determined by detailed exon sequencing [55–57]. These findings 
suggest that MMP-7 overexpression in many HNSCC cases may also be regulated by PTEN mutation. 
3.4. MMP-10 in HNSCCs  
MMP-10/stromelysin-2 constitutes a group with MMP-3/stromelysin-1. Although MMP-10 and 
MMP-3 are similar in their amino acid sequence and substrate specificity, expression patterns in 
normal and transformed cells are different [58–61]. 
According to gene expression profiling studies of MMPs, MMP-10 was highly expressed in the 
majority of HNSCC cases and could contribute to HNSCC progression (Tables 1–5 and Figures 2 and 3). 
We have reported that MMP-10 plays an important role in the invasion and metastasis of HNSCC, and 
that invasion driven by MMP-10 is partially associated with p38 MAPK inhibition. Moreover, high 
expression of MMP-10 was frequently observed by immunohistochemistry and was significantly 
correlated with invasiveness and metastasis in HNSCC cases (116 cases) [12]. These observations are 
supported by other research groups showing that the PKCι-Par6α-Rac1 signaling axis promoted 
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anchorage-independent growth and invasion of non-small-cell lung carcinoma (NSCLC) cells through 
the induction of MMP-10 expression [62]. In fact, MMP-10 expression is elevated in NSCLC tissues, 
and NSCLC patients whose tumors expressed high MMP-10 exhibited significantly worse survival 
than those whose tumors expressed low MMP-10 [62,63]. Tongue carcinoma cells treated with 
curcumin, a naturally occurring polyphenol derived from the root of Curcuma longa, inhibited cancer 
invasion through the suppression of MMP-10 expression [64]. Curcumin has been investigated as both 
a chemotherapeutic and chemopreventive agent through inhibition of NF-κB activation, leading to cell 
cycle arrest, apoptosis and suppression of proliferation. In many animal models of carcinogenesis, 
curcumin has achieved full therapeutic effects [65]. Indeed, in HNSCC, curcumin treatment resulted in 
suppression of cancer growth both in vitro and in vivo [66]. These reports suggest that tumor growth 
suppression by curcumin in vivo might also be involved in the reduction of MMP-10 expression. 
Further analyses are required in order to clarify the association of MMP-10 in cancer prevention and 
treatment by curcumin. 
3.5. MMP-12 in HNSCCs 
MMP-12 is an elastinolytic protease and degrades elastin, type IV collagen, fibronectin, laminin, 
vitronectin, entactin, heparin and chondroitin sulfate proteoglycans [67–69]. MMP-12 is mainly 
expressed by macrophages and can convert plasminogen into angiostatin. Thus, MMP-12 can 
effectively inhibit endothelial cell proliferation and angiogenesis, which limits tumor growth [70,71]. 
However, MMP-12 expression is actually increased in some cancer types including HNSCC and 
correlates with epithelial dedifferentiation and histological aggressiveness, suggesting that MMP-12 
derived from cancer cells has a different role from that secreted by macrophages [13,14,72–75]. In 
fact, some studies have shown that the expression level of MMP-12 derived from cancer cells was 
higher in aggressive and poorly differentiated squamous cell carcinoma, while macrophage-derived 
MMP-12 was not abundant in early-stage cancer [72,76]. 
MMP-12 is up-regulated in HNSCCs by gene expression profiling (Tables 1–5 and Figures 2 and 3) 
[13,14,72–74,76,77]. In addition, a recent report shows that MMP-12 expression correlates with 
extracapsular spread and nodal metastasis of HNSCCs [78]. From these findings, although MMP-12 is 
considered to be a marker for HNSCC aggressiveness, there are no studies showing whether MMP-12 
inhibition can block cancer invasion and metastasis.  
3.6. MMP-13 in HNSCCs 
Induction of angiogenesis is considered to be an important event in the metastatic cascade of 
tumors. It is widely accepted that tumor growth and metastasis are angiogenesis-dependent, and hence, 
blocking angiogenesis could be a strategy to arrest tumor growth [79]. Some MMPs, such as MMP-1,  
-2, -3, -7, -9, MT1-MMP and MT3-MMP, can contribute to distinct vascular events in tumors [80]. 
Among them, MMP-9, secreted by inflammatory cells, has a distinct role in tumor angiogenesis, by 
mainly regulating the bioavailability of vascular endothelial growth factor (VEGF). MMP-9 enables an 
angiogenic switch by increasing the bioavailability of sequestered VEGF for its receptor VEGFR-2 in 
pancreatic islet tumors [81]. In addition, the direct cleavage of matrix-bound VEGF by MMP-3, -7, -9 
or MT3-MMP results in modified VEGF molecules with altered bioavailability, which changes  
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the vascular patterning of tumors in vivo [82]. However, the degradation of ECM components and 
other extracellular molecules may generate fragments with new bioavailabilities that inhibit 
angiogenesis [83]. Thus, MMPs have dual functions as inhibiting and promoting angiogenesis, and the 
effects of MMPs on angiogenesis might be diverse. 
MMP-13 is known as collagenase-3 and is active against a wide variety of ECM components [84]. 
Repairs of bone fractures in MMP-13-deficient mice are delayed, which suggests a critical role of 
MMP-13 in the process of angiogenesis during the healing of fractures [85]. Additionally, chicken 
MMP-13 is associated with cartilage and bone resorption and collagen remodeling in the angiogenic 
process [86]. Moreover, high expression of MMP-13 has been correlated to tumor behavior and 
prognosis [87]. Recently, MMP-13 produced from stromal fibroblasts promotes angiogenesis through 
increased protein levels of VEGF and VEGFR-2 in invasive areas of cancer [88]. 
In HNSCC cases, the datasets of gene expression profiling of MMPs show that MMP-13 expression 
was highly up-regulated (Tables 1–5 and Figures 1 and 2). We have recently reported that MMP-13 
was identified as a common up-regulated gene by HNSCC invasion-related factors and involved in 
tumor angiogenesis [89]. MMP-13 enhanced capillary tube formation both in vitro using human 
umbilical vein endothelial cells and in vivo using a rat aortic ring angiogenesis assay. Interestingly, 
apart from affecting the migration of endothelial cells, MMP-13 also promoted tumor angiogenesis 
through induction of VEGF-A secretion from fibroblasts and endothelial cells. In addition, MMP-13 
expression was correlated with the number of blood vessels in HNSCC cases (64 cases). Indeed, high 
MMP-13 expression level is associated with aggressiveness of HNSCC [90]. Therefore, MMP-13 may 
have prognostic value in patient evaluation and is a potential therapeutic target for HNSCCs. 
3.7. MMP-14 (MT1-MMP) in HNSCCs 
Cancer cells form dynamic, actin-rich structures called invadopodia that localize to the  
ventral surface of cells and act as sites of matrix degradation via some types of enzymes including 
zinc-regulated metalloproteases [91–95]. MMPs are one of the major proteases that are present in 
invadopodia [96,97]. MMP-2, MMP-9 and MT1-MMP is associated with ECM degradation by 
invadopodia [98–100]. Loss of invadopodia formation in cancer cells by reduction of tyrosine kinase 
substrate with five SH3 domains (Tks5) abundance, a master regulator of invadopodia, reduced 
invasive behavior in vitro and tumorigenicity in vivo because cancer cells without invadopodia lack 
ECM degradative ability [101,102]. Furthermore, while it was previously believed that invadopodia 
are not required for cancer cell growth based on studies in monolayer cell culture, more recent studies 
reveal a role for invadopodia in growth in more physiological 3D ECM contexts [102]. Cancer cells 
with inhibition or knockout of MT1-MMP, a key proteinase localized at invadopodia structures, cannot 
grow in a 3D environment [103,104]. Some reports clearly show that the importance of invadopodia in 
HNSCC progression. Using a semi-orthotopic rat trachea model, overexpression of cortactin, one of 
the key components of invadopodia, promotes HNSCC growth in vivo through regulating an autocrine 
secretion of growth-promoting factors [105]. In addition, Clark et al. demonstrate that cortactin is  
an essential regulator of MMP secretion and ECM degradation at invadopodia in HNSCC. These  
data suggest that cortactin-induced MMP expression in invadopodia is a key event of HNSCC 
progression [99].  
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Although the results of gene expression profiling of MMPs (Tables 1, 3, 5 and Figures 1–3) and 
some other reports have shown that MT1-MMP expression increases in HNSCC cases and plays an 
important role in the formation of functional invadopodia during cancer progression [8,106–109], there 
are still significant technical problems that need to be solved for clinical assessment of cancer 
progression targeting invadopodia. The components of the invadopodia structure are also generally 
expressed in normal cells, and it is difficult to detect invadopodia as actin-rich structures in clinical 
specimens. Therefore, it may be required to identify a signature that is specifically expressed in 
invadopodia-forming cancer cells. 
3.8. MMP-19 in HNSCCs 
MMP-19, MMP-18, RASI-1, was cloned from a human liver cDNA library [110,111] and 
characterized as an enzyme that can cleave various ECM components, such as collagen IV, fibronectin 
and aggrecan [112,113]. Expression of MMP-19 is known in many cell types and its expression pattern 
is modulated according to the circumstances. Djonov et al. have reported that MMP-19 is strongly 
expressed in myoepithelial layer of the breast ductal tissue, benign tumor and their surrounding 
vasculature, but not in invasive tumor lesions [114]. In oropharyngeal squamous cell carcinoma, 
expression of MMP-19 is observed in healthy tissue areas, non-invasive tumor parts and also tumor 
invasive front, but its expression is absent in neoplastic regions [115]. Recent reports show that MMP-19 
expression is increased in melanoma, ovarian cancer and glioma [116–118]. Müller et al. have shown 
that MMP-19 expression is up-regulated in melanoma vertical growth phase and metastases, and 
ectopic expression of MMP-19 facilitates transmigratory capacity through collagen type IV [116]. 
Triptolide, a compound extracted from the traditional chinese medicine preparation of Tripterygium 
wilfordii Hook F., can inhibit ovarian cancer invasion and tumor growth in vivo through transcriptional 
suppression of MMP-7 and MMP-19 [117]. Although expression of MMP-19 is up-regulated in some 
of the gene expression profiling (Tables 1, 3 and 5), there is no report showing MMP-19 protein 
expression in HNSCC cases and experimental data that reveals role of MMP-19 in HNSCCs. Kudo et al. 
have demonstrated that highly invasive HNSCC cell line, MSCC-inv1, significantly overexpressed 
MMP-19 [4]. This suggests that MMP-19 may have a potential to facilitate HNSCC invasiveness. 
Further analyses are required to assess the role of MMP-19 in HNSCCs. 
4. Conclusions 
Gene expression profiling by microarray analysis indicates that many MMPs are highly expressed 
and contribute to tumor progression and poor outcome in various cancers including HNSCC. Among 
various cancers, HNSCC is well used for the study on MMPs. Here we introduced the roles of some 
MMPs, especially MMP-1, -3, -7, 10, -12, -13, -14 and -19 in HNSCC. Although the roles of MMPs in 
cancer behavior are evident, the agents targeting MMPs exhibited poor performance in clinical trials 
because of unknown side effects. MMPs are involved in not only ECM degradation for tumor 
dissemination, but also many important normal processes, such as cytokine activation and cleavage of 
cell-surface receptors. Thus, inhibiting MMPs could interfere with normal cellular behavior. Moreover, 
the spatio-temporal pattern of MMP expression both in normal and cancer tissues is complex and 
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confusing. To reduce the unknown effects of MMP inhibitors, further analyses are needed to 
understand the entire aspect of MMP expression and modulation in all organs and cells. 
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